Cybin Inc. (CYBN)
(Delayed Data from AMEX)
$0.27 USD
0.00 (0.26%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.27 0.00 (0.75%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CYBN 0.27 0.00(0.26%)
Will CYBN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CYBN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CYBN
What Makes Cybin Inc. (CYBN) a New Buy Stock
Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround
CYBN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?
Brian's Big Idea on Biotech
Other News for CYBN
Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report
Psychedelic Stocks: Focus On Their Cash
Lykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
Cybin Prepares for Phase 3 Trial of Depression Treatment